• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NTI

NEUROTECH INTERNATIONAL LIMITED - Announcements

0.00% ! 1.3¢
Market Cap $13.64M  !

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
1.3¢
Change
0.000(0.00%)
Mkt cap ! $13.64M
Open High Low Value Volume
1.3¢ 1.3¢ 1.3¢ $506 38.89K

Buyers (Bids)

No. Vol. Price($)
13 2868143 1.2¢
 

Sellers (Offers)

Price($) Vol. No.
1.3¢ 1088141 4
View Market Depth
Last trade - 09.59am 05/09/2025 (20 minute delay) ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.